Kate Cwynarski, MD, PhD, University College Hospital, London, UK, review recent data in secondary CNS lymphoma presented at ASH 2019, BSH 2020 and EHA 2020. Dr Cwynarski specifically discusses the IELSG 42 study evaluating the MARIETTA regimen in CNS lymphoma patients. Historically, CNS lymphoma has had poor outcomes, however, it is hoped that with larger, randomized trials as well as novel treatment approaches, there may be improved results in patients with this indication. This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).
15 июл 2020
